These findings support the development of strategies attempting to increase α-KG levels by inhibition of BCAT1 to inhibit leukemic stem cells and thus to improve the outcome of AML patients, expressing high levels of BCAT1, not associated with TET2 or IDH mutations. Here, BCAT1 is linked to acute myeloid leukemia.